These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 22569341

  • 1. Soluble urokinase receptor and focal segmental glomerulosclerosis.
    Reiser J, Wei C, Tumlin J.
    Curr Opin Nephrol Hypertens; 2012 Jul; 21(4):428-32. PubMed ID: 22569341
    [Abstract] [Full Text] [Related]

  • 2. Management of severe recurrent focal segmental glomerulosclerosis through circulating soluble urokinase receptor modification.
    Morath C, Wei C, Macher-Goeppinger S, Schwenger V, Zeier M, Reiser J.
    Am J Ther; 2013 Jul; 20(2):226-9. PubMed ID: 23466622
    [Abstract] [Full Text] [Related]

  • 3. Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation.
    Staeck O, Slowinski T, Lieker I, Wu K, Rudolph B, Schmidt D, Brakemeier S, Neumayer HH, Wei C, Reiser J, Budde K, Halleck F, Khadzhynov D.
    Transplantation; 2015 Dec; 99(12):2593-7. PubMed ID: 26371597
    [Abstract] [Full Text] [Related]

  • 4. suPAR and chronic kidney disease-a podocyte story.
    Zeier M, Reiser J.
    Pflugers Arch; 2017 Aug; 469(7-8):1017-1020. PubMed ID: 28689240
    [Abstract] [Full Text] [Related]

  • 5. Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View.
    Kronbichler A, Saleem MA, Meijers B, Shin JI.
    J Immunol Res; 2016 Aug; 2016():2068691. PubMed ID: 27504461
    [Abstract] [Full Text] [Related]

  • 6. Permeability factors in focal and segmental glomerulosclerosis.
    Reiser J, Nast CC, Alachkar N.
    Adv Chronic Kidney Dis; 2014 Sep; 21(5):417-21. PubMed ID: 25168830
    [Abstract] [Full Text] [Related]

  • 7. [Value of soluble urokinase receptor serum levels in the differential diagnosis between idiopathic and secondary focal segmental glomerulosclerosis].
    Segarra A, Jatem E, Quiles MT, Arbós MA, Ostos H, Valtierra N, Carnicer C, Salcedo MT.
    Nefrologia; 2014 Sep; 34(1):53-61. PubMed ID: 24463863
    [Abstract] [Full Text] [Related]

  • 8. Primary and Recurrent Focal Segmental Glomerulosclerosis Closely Link to Serum Soluble Urokinase-type Plasminogen Activator Receptor Levels.
    Jin J, Li YW, He Q.
    Transplant Proc; 2015 Sep; 47(6):1760-5. PubMed ID: 26293047
    [Abstract] [Full Text] [Related]

  • 9. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.
    Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, Maiguel D, Karumanchi SA, Yap HK, Saleem M, Zhang Q, Nikolic B, Chaudhuri A, Daftarian P, Salido E, Torres A, Salifu M, Sarwal MM, Schaefer F, Morath C, Schwenger V, Zeier M, Gupta V, Roth D, Rastaldi MP, Burke G, Ruiz P, Reiser J.
    Nat Med; 2011 Jul 31; 17(8):952-60. PubMed ID: 21804539
    [Abstract] [Full Text] [Related]

  • 10. Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantation.
    Harel E, Shoji J, Abraham V, Miller L, Laszik Z, Thurison T, King A, Olshen A, Leung J, Szabo G, Hann B, Høyer-Hansen G, Craik CS, Vincenti F.
    Clin Transplant; 2019 Mar 31; 33(3):e13487. PubMed ID: 30689221
    [Abstract] [Full Text] [Related]

  • 11. Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.
    Chen JS, Chang LC, Wu CZ, Tseng TL, Lin JA, Lin YF, Cheng CW.
    J Biomed Sci; 2016 Feb 04; 23():24. PubMed ID: 26846181
    [Abstract] [Full Text] [Related]

  • 12. CD80, suPAR and nephrotic syndrome in a case of NPHS2 mutation.
    Cara-Fuentes G, Araya C, Wei C, Rivard C, Ishimoto T, Reiser J, Johnson RJ, Garin EH.
    Nefrologia; 2013 Feb 04; 33(5):727-31. PubMed ID: 24089165
    [Abstract] [Full Text] [Related]

  • 13. Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates.
    Franco Palacios CR, Lieske JC, Wadei HM, Rule AD, Fervenza FC, Voskoboev N, Garovic VD, Zand L, Stegall MD, Cosio FG, Amer H.
    Transplantation; 2013 Aug 27; 96(4):394-9. PubMed ID: 23736353
    [Abstract] [Full Text] [Related]

  • 14. Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis.
    Huang J, Liu G, Zhang YM, Cui Z, Wang F, Liu XJ, Chu R, Zhao MH.
    BMC Med; 2014 May 20; 12():81. PubMed ID: 24884842
    [Abstract] [Full Text] [Related]

  • 15. Decreased glomerular filtration as the primary factor of elevated circulating suPAR levels in focal segmental glomerulosclerosis.
    Harita Y, Ishizuka K, Tanego A, Sugawara N, Chikamoto H, Akioka Y, Tsurumi H, Miura K, Gotoh Y, Tsujita M, Yamamoto T, Horike K, Takeda A, Oka A, Igarashi T, Hattori M.
    Pediatr Nephrol; 2014 Sep 20; 29(9):1553-60. PubMed ID: 24705794
    [Abstract] [Full Text] [Related]

  • 16. Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy.
    Alachkar N, Wei C, Arend LJ, Jackson AM, Racusen LC, Fornoni A, Burke G, Rabb H, Kakkad K, Reiser J, Estrella MM.
    Transplantation; 2013 Oct 15; 96(7):649-56. PubMed ID: 23842190
    [Abstract] [Full Text] [Related]

  • 17. Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis.
    Huang J, Liu G, Zhang YM, Cui Z, Wang F, Liu XJ, Chu R, Chen Y, Zhao MH.
    Kidney Int; 2013 Aug 15; 84(2):366-72. PubMed ID: 23447064
    [Abstract] [Full Text] [Related]

  • 18. Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method.
    Winnicki W, Sunder-Plassmann G, Sengölge G, Handisurya A, Herkner H, Kornauth C, Bielesz B, Wagner L, Kikić Ž, Pajenda S, Reiter T, Schairer B, Schmidt A.
    Sci Rep; 2019 Sep 24; 9(1):13783. PubMed ID: 31551522
    [Abstract] [Full Text] [Related]

  • 19. Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab.
    Alachkar N, Li J, Matar D, Vujjini V, Alasfar S, Tracy M, Reiser J, Wei C.
    BMC Nephrol; 2018 Dec 17; 19(1):361. PubMed ID: 30558559
    [Abstract] [Full Text] [Related]

  • 20. Removal of focal segmental glomerulosclerosis (FSGS) factor suPAR using CytoSorb.
    Schenk H, Müller-Deile J, Schmitt R, Bräsen JH, Haller H, Schiffer M.
    J Clin Apher; 2017 Dec 17; 32(6):444-452. PubMed ID: 28370393
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.